Incident Score: Analysis & Impact (NOV1774449180)
The details regarding individual company incidents & reports gives you full view from every side.
Rankiteo Score Impact Analysis
Key Highlights From The Incident Analysis
- Timeline of Novartis's Breach and lateral movement inside company's environment.
- Overview of affected data sets, including SSNs and PHI, and why they materially increase incident severity.
- How Rankiteo’s incident engine converts technical details into a normalized incident score.
- How this cyber incident impacts Novartis Rankiteo cyber scoring and cyber rating.
- Rankiteo’s MITRE ATT&CK correlation analysis for this incident, with associated confidence level.
Full Incident Analysis Transcript
In this Rankiteo incident briefing, we review the Novartis breach identified under incident ID NOV1774449180.
The analysis begins with a detailed overview of Novartis's information like the linkedin page: https://www.linkedin.com/company/novartis, the number of followers: 4496111, the industry type: Pharmaceutical Manufacturing and the number of employees: 82910 employees
After the initial compromise, the video explains how Rankiteo's incident engine converts technical details into a normalized incident score. The incident score before the incident was 835 and after the incident was 807 with a difference of -28 which is could be a good indicator of the severity and impact of the incident.
In the next step of the video, we will analyze in more details the incident and the impact it had on Novartis and their customers.
Novartis recently reported "Novartis Faces Class Action Lawsuit Over Alleged Unauthorized Sharing of Patient Health Data", a noteworthy cybersecurity incident.
A Vermont-based cancer patient filed a class action lawsuit against Novartis, accusing the company of illegally sharing her sensitive health information with third parties, including Google and ContentSquare, via tracking pixels embedded on its drug websites.
The disruption is felt across the environment, affecting Novartis drug websites (e.g., Kisqali, Cosentyx, Entresto, Leqvio, Pluvicto), and exposing Patient health information, personally identifiable information (PII).
Formal response steps have not been shared publicly yet.
The case underscores how Ongoing (lawsuit pending).
Finally, we try to match the incident with the MITRE ATT&CK framework to see if there is any correlation between the incident and the MITRE ATT&CK framework.
The MITRE ATT&CK framework is a knowledge base of techniques and sub-techniques that are used to describe the tactics and procedures of cyber adversaries. It is a powerful tool for understanding the threat landscape and for developing effective defense strategies.
MITRE ATT&CK® Correlation Analysis
Rankiteo's analysis has identified several MITRE ATT&CK tactics and techniques associated with this incident, each with varying levels of confidence based on available evidence. Under the Initial Access tactic, the analysis identified Drive-by Compromise (T1189) with moderate confidence (60%), supported by evidence indicating patients visited the drug’s website to access information. Under the Collection tactic, the analysis identified Data Staged: Local Data Staging (T1074.001) with moderate to high confidence (80%), supported by evidence indicating tracking pixels and other tools on its website, transmitting P.M.’s private data and Data from Web Application Repositories (T1213.003) with moderate to high confidence (70%), supported by evidence indicating embedded tracking pixels and other tools on its drug websites. Under the Exfiltration tactic, the analysis identified Exfiltration Over C2 Channel (T1041) with high confidence (90%), supported by evidence indicating transmitting P.M.’s private data without her consent to Google and ContentSquare and Transfer Data to Cloud Account (T1537) with moderate to high confidence (80%), supported by evidence indicating shared with third parties, including Google and ContentSquare. Under the Impact tactic, the analysis identified Data Destruction (T1485) with lower confidence (30%), supported by evidence indicating violation of medical confidentiality and emotional distress and Stored Data Manipulation (T1565.001) with lower confidence (40%), supported by evidence indicating unauthorized sharing of patient health data for marketing. Under the Defense Evasion tactic, the analysis identified Hide Artifacts: Hidden Files and Directories (T1564.001) with moderate confidence (50%), supported by evidence indicating embedded tracking pixels and other tools on its website. These correlations help security teams understand the attack chain and develop appropriate defensive measures based on the observed tactics and techniques.
Sources & References
- Novartis Rankiteo Cyber Incident Details: https://www.rankiteo.com/company/novartis/incident/NOV1774449180
- Novartis CyberSecurity Rating page: https://www.rankiteo.com/company/novartis
- Novartis Rankiteo Cyber Incident Blog Article: https://blog.rankiteo.com/nov1774449180-novartis-breach-february-2026/
- Novartis CyberSecurity Score History: https://www.rankiteo.com/company/novartis/history
- Novartis CyberSecurity Incident Source: https://pharmaphorum.com/news/patient-sues-novartis-claiming-data-tracking-privacy-breach
- Rankiteo A.I CyberSecurity Rating methodology: https://www.rankiteo.com/Images/rankiteo_algo.pdf
- Rankiteo TPRM Scoring methodology: https://static.rankiteo.com/model/rankiteo_tprm_methodology.pdf